Evicenter
MarkdownMedical informationP&T meetings

Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Section 2 of 6

Executive summary

17 evidence topics · 55 sources

Clinical benefits of Barzolvolimab

Burden of Chronic spontaneous urticaria

Summary: definition and classification

The international guideline defines chronic urticaria (CU) as wheals, angioedema, or both occurring for more than 6 weeks, and classifies chronic spontaneous urticaria (CSU) as the form with no definite eliciting factor. CSU was previously known as chronic idiopathic urticaria. The draft AAAAI/ACAAI Joint Task Force guideline states that “60% of CU have CSU alone”. The international guideline attributes the signs and symptoms to activation of skin mast cells and the release of their mediators, and states that in more than 50% of patients with CSU the pathophysiology is driven by type I (autoallergy) and type IIb autoimmune mechanisms.

Summary: United States prevalence and incidence

US estimates depend on the population counted and the case definition:

  • Chronic urticaria, point prevalence: 0.1% (95% CI 0.1 to 0.1) in Northern American studies in a meta-analysis of population-based studies, compared with 0.5% in Europe and 1.4% in Asia.
  • Chronic urticaria, adults in electronic health records: 0.23%, or 230 cases per 100,000 adults, in a cross-sectional analysis of more than 55 million people; the authors estimate that more than 500,000 people in the United States have CU. Adjusted prevalence was 310 per 100,000 in women and 146 per 100,000 in men.
  • Diagnosed CSU (2 or more ICD-9 or ICD-10 codes recorded at least 6 weeks apart), period prevalence in three US databases from 2012 to 2018 (MarketScan to 2017): 0.120% to 0.277% among adults and 0.193% to 0.304% among pediatric patients. Annual adult prevalence rose from 0.052% in 2012 to 0.191% in 2018, and adult incidence ranged from 0.039 to 0.102 per 100 person-years. This study was funded by Novartis.
  • Diagnosed CSU, cumulative prevalence in adults in HealthVerity claims from 2017 to 2022: 0.57% (women 0.80%; men 0.32%), with an average annual incidence of 0.08%. At least one author is affiliated with US Medical Affairs, Novartis Pharmaceuticals Corp.
  • Self-reported CSU diagnosed by a healthcare provider in the past 12 months, adults in the 2019 National Health and Wellness Survey: weighted prevalence 0.78% (95% CI 0.78% to 0.78%); 635 of 74,994 respondents reported CSU. This study was funded by Novartis.

In the international CURE registry, 2994 of 4136 participants with CSU (72.4%) were female.

Summary: natural history, duration, and mortality
  • Course: the international guideline states that CU can have daily or almost daily signs and symptoms or an intermittent or recurrent course, that CSU episodes may recur after months or years of full remission, and that concomitant chronic inducible urticaria, high disease activity, elevated CRP, or angioedema indicate a prolonged duration and suboptimal response to antihistamines.
  • Remission: a targeted literature review of 10 publications estimated cumulative weighted average remission of 17% at year 1, 45% at year 5, and 73% at year 20, and states that the average disease duration in CSU has been estimated to be 5 years. In an electronic health record cohort of 112,443 adults with CU, median time to clinical remission ranged from 4.1 months (cluster 1, 32.6% of participants, relapse rate 38.0%) to 33.8 and 44.6 months (clusters 3 and 4, 21.4% and 19.4% of participants, relapse rates 75%).
  • Duration in the United States: mean (SD) disease duration was 11.0 (12.6) years among survey respondents with physician-diagnosed CSU.
  • Mortality: in a TriNetX cohort of 264,680 propensity score-matched adults with CSU and the same number of controls, all-cause mortality hazard ratios were 2.10 at 3 months, 1.77 at 1 year, and 1.69 at 5 years. The authors state that no causal inferences can be drawn because the database cannot identify the cause of death.
Summary: clinical presentation and comorbidities
  • Presentation: wheals are circumscribed superficial swellings with reflex erythema and itch or burning that resolve within 30 minutes to 24 hours; angioedema is a deeper swelling with tingling, burning, tightness, or pain that can take up to 72 hours to resolve.
  • Angioedema: among 673 adults with inadequately controlled CSU, medical records documented CSU-associated angioedema in 58.5% (394 of 673), and 65.8% (427 of 649) reported angioedema in the previous 12 months. Among US survey respondents with physician-diagnosed CSU, 49.1% reported angioedema in the past 3 months.
  • Comorbidities: the international guideline names chronic inducible urticaria, autoimmune diseases, metabolic syndrome, and allergies as the most common comorbidities, and depression, anxiety, sexual dysfunction, and sleep disturbance as common consequences. Most studies report IgG antithyroid autoantibodies in 10% or more of patients with CSU. In a meta-analysis of participants with chronic urticaria, 56,258 of 177,998 (31.61%) had a psychiatric comorbidity, compared with 4.6% of controls.
  • US claims: among 224,958 adults with CSU, the proportion with claims for mental health conditions rose from 40.6% at baseline to 56.3% during follow-up, and for sleep-related conditions from 8.8% to 15.4%. In the TriNetX electronic health record cohort, compared with controls, adults with CSU had hazard ratios of 3.14 for suicidal ideations or suicide attempts and 2.09 for malignant neoplasms.
Summary: humanistic burden
  • In 673 adults whose CSU persisted for 12 months or more despite treatment, mean (SD) Dermatology Life Quality Index (DLQI) was 9.1 (6.62), more than 40% had a DLQI of 10 or greater, and productivity impairment was 27%. This study was funded by Novartis.
  • Among US adults with self-reported physician-diagnosed CSU in the 2019 National Health and Wellness Survey, mean (SD) SF-6D and EQ-5D utilities were 0.54 (0.14) and 0.62 (0.34), mean DLQI was 13.8 (11.2), 54.2% had a DLQI above 10, more than 74.0% reported anxiety (GAD-7 of 5 or more) and depression (PHQ-9 of 5 or more), and mean overall work impairment was 73.1%. This study was funded by Novartis.
  • In another analysis of the 2019 US National Health and Wellness Survey, mean mental and physical component summary scores were 41.3 and 42.1 with CSU, 44.8 and 47.8 with atopic dermatitis, and 45.3 and 47.7 with psoriasis (all p < 0.001).
  • In a multinational online survey of 582 participants with CSU, 84% of those taking antihistamines were inadequately controlled (UCT score below 12), and participants reported a mean diagnostic delay of 2 years.
Summary: economic burden
  • In a commercially insured US population (research paid for by Genentech), CSU prevalence was 0.11%; mean all-cause healthcare costs were US$9142 per year (SD US$21,835; median US$3659) and mean urticaria-related costs were US$997; oral corticosteroids were used by 54.7% and participants had a mean of 15.1 office visits per year.
  • In US HealthVerity claims, more than 50% of patients prescribed treatment had uncontrolled CSU, which was associated with increased healthcare resource use and costs.
  • In the international ASSURE-CSU study, annual direct costs per patient ranged from PPP$907.1 in Italy to PPP$2984.2 in France, out-of-pocket expenses averaged nearly PPP$500 per year, 14.4% of participants had at least one CSU-related emergency department visit in the past 12 months, and 8.2% had a recorded hospitalization for CSU.
  • In 2024 Oregon all-payer claims, 901 enrollees had 8,833 Xolair claims, with approximately $19.5 million in total gross payer spending and approximately $21,618 in annual gross payer spending per enrollee.
  • In children younger than 12 years, CIU/CSU was associated with higher per patient per year costs than matched controls: a mean cost difference of $1853 among Medicaid enrollees and $2090 among commercially insured children.

Barzolvolimab efficacy and safety

Summary: phase 3 EMBARQ-CSU1 efficacy at Weeks 12 and 24

EMBARQ-CSU1 (NCT06445023) is a randomized, double-blind, placebo-controlled phase 3 trial in adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. It randomized 963 participants to barzolvolimab 150 mg every 4 weeks (after a 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (after a 450 mg loading dose), or placebo; the full analysis set comprised N=325 (placebo), N=320 (150 mg), and N=318 (300 mg). The company reported “topline results” with a data cutoff of September 9, 2026.

  • Primary endpoint, mean change from baseline in UAS7 at Week 12 (LS mean change, SE): -10.7 (0.65) with placebo, -20.2 (0.64) with 150 mg every 4 weeks, and -20.5 (0.65) with 300 mg every 8 weeks, from baseline UAS7 values of 30.9, 30.6, and 30.3; p<.00001 for each dose, with p-values for the LS mean treatment difference versus placebo.
  • Treatment difference versus placebo (LS mean, 97.5% CI; full analysis set, imputed data and MMRM model): -9.5 (-11.5, -7.4) for 150 mg every 4 weeks and -9.8 (-11.9, -7.8) for 300 mg every 8 weeks.
  • Complete response (UAS7=0) at Week 12, as adjusted proportions from a logistic regression model with multiple imputation: 9.3% with placebo, 42.4% with 150 mg, and 42.1% with 300 mg (p<.00001 for each, based on adjusted odds ratios).
  • UAS7=0 at Week 24, presented by the company: 15.4%, 49.0%, and 45.1% (p<.00001 for each).
  • UAS7=0 at Week 12 in omalizumab-refractory participants (N=55, 52, and 52): 9.3%, 55.3% (p<.00001), and 44.3% (p=.00017).
  • AAS7=0 at Week 12 in participants with baseline AAS7>0 (N=237, 238, and 239): 33.8%, 62.7%, and 66.3% (p<.00001 for each).
  • The company states that all key secondary endpoints were met at Week 12 in both trials; for ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants, it reports no values.
Summary: phase 3 EMBARQ-CSU2 efficacy at Weeks 12 and 24

EMBARQ-CSU2 (NCT06455202) is a randomized, double-blind, placebo-controlled phase 3 trial with a 24-week placebo-controlled treatment period, comparing barzolvolimab 150 mg every 4 weeks (after a 300 mg loading dose) and 300 mg every 8 weeks (after a 450 mg loading dose) with placebo. It randomized 976 participants; the full analysis set comprised N=321 (placebo), N=324 (150 mg every 4 weeks), and N=321 (300 mg every 8 weeks). Data cutoff was September 9, 2026.

  • Primary endpoint, mean change from baseline in UAS7 at Week 12 (LS mean change, SE): -11.4 (0.64) with placebo, -20.2 (0.63) with 150 mg every 4 weeks, and -19.7 (0.64) with 300 mg every 8 weeks, from baseline UAS7 values of 29.3, 29.7, and 29.6; p<.00001 for each dose.
  • Treatment difference versus placebo (LS mean, 97.5% CI; full analysis set, imputed data and MMRM model): -8.9 (-10.9, -6.9) for 150 mg every 4 weeks and -8.3 (-10.4, -6.3) for 300 mg every 8 weeks.
  • UAS7=0 at Week 12 (adjusted proportions, logistic regression with multiple imputation): 12.6% with placebo, 45.7% with 150 mg, and 44.0% with 300 mg (p<.00001 for each).
  • UAS7=0 at Week 24, presented by the company: 17.6%, 54.0%, and 48.4% (p<.00001 for each).
  • UAS7=0 at Week 12 in omalizumab-refractory participants (N=43, 44, and 42): 15.1%, 41.7% (p=.0089), and 46.4% (p=.0036).
  • AAS7=0 at Week 12 in participants with baseline AAS7>0 (N=206, 213, and 217): 33.7%, 74.3%, and 66.2% (p<.00001 for each).
Summary: phase 2 efficacy at Weeks 12, 52, and 76

In a phase 2 double-blind, placebo-controlled trial (NCT05368285), adults with antihistamine-refractory CSU (UAS7 ≥ 16) were randomized 1:1:1:1 to barzolvolimab 75 mg every 4 weeks (n = 53), 150 mg every 4 weeks (n = 52), 300 mg every 8 weeks (n = 51 in the publication; n=52 in the 52-week presentation), or placebo (n = 51). At Week 16, participants receiving placebo or 75 mg were re-randomized to 150 mg every 4 weeks or 300 mg every 8 weeks.

  • Week 12 (primary analysis): the mean (95% CI) difference from placebo in UAS7 change from baseline was -6.60 (-10.71, -2.49; P = .0017) with 75 mg, -12.55 (-16.56, -8.55; P < .0001) with 150 mg, and -13.41 (-17.47, -9.34; P < .0001) with 300 mg. UAS7 ≤ 6 was reached by 41.7%, 59.6%, and 62.5% compared with 12.8% with placebo (P < .01 for all comparisons), and UAS7 = 0 by 22.9%, 51.1%, and 37.5% compared with 6.4% (P < .05 for all comparisons).
  • Week 52 (interim data cut July 31, 2024): UAS7 = 0 was reported in 71.1% of the 150 mg group, 52.3% of the 300 mg group, 53.5% of the group switched from 75 mg, and 58.7% of the group switched from placebo; UAS7 ≤ 6 in 73.7%, 68.2%, 67.4%, and 63.0%.
  • Week 76, 28 weeks after the last dose (modified intent to treat, observed data): UAS7 mean change from baseline (SE) was -20.4 (2.5) with 150 mg and -21.1 (1.9) with 300 mg; UAS7=0 was reported in 41% and 35%, and UAS7≤6 in 56% and 47%. Of participants treated with 150 mg or 300 mg for 1 year who had well-controlled disease after 52 weeks of treatment, 69% also had well-controlled disease and 50% a complete response at Week 76.
Summary: phase 1b efficacy with intravenous dosing

In a phase 1b randomized, double-blind, placebo-controlled study (NCT04538794) in antihistamine-refractory CSU, participants were randomly assigned 4:1 to intravenous barzolvolimab (0.5 mg/kg or 1.5 mg/kg every 4 weeks, or 3.0 mg/kg or 4.5 mg/kg every 8 weeks) or placebo over 12 weeks; 35 participants received barzolvolimab and 10 received placebo.

  • By Week 12, 71.4% of barzolvolimab-treated participants had UAS7 ≤ 6 compared with 30.0% with placebo, and 57.1% had UAS7 = 0 compared with 20%. UCT ≥ 12 was reached by 77.1% and UCT = 16 by 42.9% of barzolvolimab-treated participants.
  • More than 50% of participants at doses ≥ 1.5 mg/kg remained urticaria free at Week 24, 16 weeks after their last dose. The 0.5 mg/kg dose produced transient improvements.
  • In participants with prior omalizumab treatment at pooled doses ≥ 1.5 mg/kg, UAS7 = 0 and UAS7 ≤ 6 by Week 12 were observed in 53.8% and 84.6%.
Summary: phase 3 adverse events and anaphylaxis through Week 24, pooled EMBARQ-CSU1 and EMBARQ-CSU2

Safety through the 24-week placebo-controlled period is reported pooled across both phase 3 trials for placebo (N=645), barzolvolimab 150 mg every 4 weeks (N=648), and barzolvolimab 300 mg every 8 weeks (N=641), as n (%).

  • At least 1 adverse event: 340 (52.7), 490 (75.6), and 492 (76.8).
  • Hair color changes: 29 (4.5), 292 (45.1), and 330 (51.5). Skin hypopigmentation: 16 (2.5), 71 (11.0), and 64 (10.0). Skin hyperpigmentation: 5 (0.8), 59 (9.1), and 58 (9.1).
  • Neutropenia: 4 (0.6), 59 (9.1), and 75 (11.7). Anemia: 4 (0.6), 20 (3.1), and 20 (3.1). Infection rates were 23.9%, 24.4%, and 23.6%, and the company states that neutropenia was not associated with increased incidence of infections.
  • Dysgeusia: 9 (1.4), 44 (6.8), and 63 (9.8). Hypogeusia: 10 (1.6), 33 (5.1), and 53 (8.3).
  • Serious adverse events: 15 (2.3), 6 (0.9), and 14 (2.2); treatment-related serious adverse events: 1 (0.2), 3 (0.5), and 4 (0.6).
  • Anaphylaxis adjudicated as probable (G4): 0 with placebo, 2 with 150 mg, and in the 300 mg group “1 (occurred after placebo dose)”. Other anaphylaxis events numbered 1, 1, and 3; the footnotes list grade 3 anaphylaxis adjudicated as unlikely (placebo), grade 2 angioedema/throat tightness/urticaria (150 mg), and grade 3 anemia/neutropenia, grade 2 malaise/dyspnea/chest pain, and grade 3 anaphylaxis after placebo administration (300 mg).
Summary: neutropenia, pigmentation and taste changes, discontinuations, reversibility, and immunogenicity in phase 1b and phase 2
  • Phase 2, Week 12: 88 barzolvolimab-treated participants (56.4%) and 14 placebo participants (27.5%) reported a TEAE. Neutropenia (neutropenia and neutrophil count decreased) occurred in 12 (7.7%) pooled barzolvolimab participants and none with placebo and was not associated with infections; hair color changes occurred in 14 (9.0%). A TEAE led to treatment discontinuation in 7 barzolvolimab-treated participants (4.5%) and in no placebo participant.
  • Phase 2, Weeks 0 to 52 (all doses, N = 156): hair color changes 40 (26%), neutropenia or neutrophil count decreased 26 (17%), and skin hypopigmentation 21 (13%); 2 (1%) treatment-related serious adverse events. Treatment was discontinued for an adverse event by 7 (13%), 4 (8%), 7 (13%), and 2 (4%) participants in the 75 mg, 150 mg, 300 mg, and placebo-then-barzolvolimab groups; adverse events leading to discontinuation in more than one participant were hair color changes (6), urticaria (5), and macrocytic anemia (2).
  • Phase 2 pigmentation over 76 weeks (204 participants who received at least one dose): hair color changes in 49 (24%), 96% grade 1, with resolution reported by 91% of evaluable participants by the end of study participation; skin hypopigmentation in 36 (18%), with 68% resolved by data cutoff; skin hyperpigmentation in 6 (3%), with 67% resolved. Discontinuation for pigmentation changes was 6 (3%) for hair color changes, 0 for skin hypopigmentation, and 1 (<0.5%) for skin hyperpigmentation.
  • Reversibility: the company reports that neutrophil counts returned to baseline after completion of treatment and that hair color changes and skin hypopigmentation were reversible after treatment was discontinued.
  • Phase 1b (intravenous, N = 35 barzolvolimab, N = 10 placebo): 30 (86%) and 6 (60%) had a TEAE in the publication (5 (50%) with placebo in the November 2022 data cutoff poster); hair color changes occurred in 9 (26%) in the publication (8 (23%) in the poster), 7 of whom had the event resolve by the end of the study; neutropenia occurred in 5 (14%); taste changes were reported by three participants (< 10%). Three participants had grade 3 decreased neutrophils, which resolved, and no TEAE led to treatment discontinuation.
  • Immunogenicity: in the phase 1b study, 57% (20/35) of participants were ADA positive in the publication, with drug-related adverse events similar in ADA-positive and ADA-negative participants and no apparent effect on exposure; a poster at the November 29, 2022 data cut reported treatment-emergent ADA in 51%. No ADA results from the phase 2 or phase 3 CSU trials were found, and no phase 3 counts of discontinuation for adverse events have been released.

Budget impact of Barzolvolimab

Summary: price status and comparator prices
  • The company anticipates a BLA submission to the FDA for barzolvolimab in CSU in 2027. No published price and no budget impact model for barzolvolimab were found.
  • Remibrutinib (Rhapsido): list (or wholesale) price of $4,521 per package (30-day supply, 60 tablets) as of January 7, 2026.
  • Dupilumab (Dupixent): $4,193.03 per 4-week supply, defined as two injections, with pricing as of January 1, 2026. The Oregon PDAB review lists a 2025 WAC of $3,993 per 30-day supply for 300 mg every 2 weeks.
  • Omalizumab (Xolair): Genentech states a current list price (WAC) of approximately $30,000 - $60,000 annually. The Oregon PDAB review states a WAC of approximately $1472.76 per unit at the end of 2025, an average annual unit WAC increase of 4.9 percent between 2019 and 2025, and a 2025 WAC of $5,891 per 30-day supply for 600 mg every 1 month.
  • The draft AAAAI/ACAAI joint task force guideline lists direct prices as of December 2025 of $1475 per month for omalizumab, $4,193.03 per carton for dupilumab, and $4,424.01 per bottle of 60 tablets for remibrutinib.
  • In the 2024 Oregon All Payer All Claims data, 901 enrollees had 8,833 Xolair claims, with approximately $19.5 million in total gross payer spending and approximately $21,618 in annual gross payer spending per enrollee.
  • The Oregon PDAB review states that omalizumab biosimilar competition became available in 2026 and that Xolair was selected for the third cycle of the Medicare Drug Price Negotiation Program, with any negotiated Maximum Fair Price scheduled to take effect January 1, 2028. Healio reports that the biosimilar Omlyclo is commercially available in the U.S.
  • Celldex states a CSU prevalence of 0.5-1.0% of the total population, or up to approximately 1 to 3 million patients in the United States, and that approximately 50% of patients with CSU achieve symptomatic control with antihistamines. Its topline presentation states that 25-35% of patients with CSU are assessed as severe and projects that the second-line advanced therapy market will eclipse the first-line market.
Summary: cost-effectiveness analyses and health technology assessments of comparators
  • Omalizumab, NICE TA339: the company's revised deterministic base case with the patient access scheme gave an ICER of £27,469 per QALY gained (around £26,000 per QALY gained in severe disease at baseline). NICE recommends omalizumab for severe CSU only when severity is assessed objectively, for example a UAS7 of 28 or more, and when it is stopped at or before the fourth dose if the condition has not responded.
  • Omalizumab versus standard of care, UK societal perspective (Novartis-funded): deterministic base-case ICER of £3183 over a 20-year time horizon, with productivity inputs as key model drivers.
  • Omalizumab versus standard of care, Netherlands societal perspective: ICER of €17 502 per QALY gained, and €85 310 per QALY when productivity costs were discarded.
  • Omalizumab versus standard treatment, China, patient perspective: ICER of ¥160,411/QALY.
  • Remibrutinib with cetirizine versus cetirizine alone, US healthcare sector perspective (conference poster): ICER of $3,208,966 per QALY over 10 years and $232,084 per QALY over 24 weeks; remibrutinib was not cost-effective at a willingness to pay of $150,000 per QALY.
  • Remibrutinib, NICE draft guidance (September 2026): remibrutinib “should not be used” for CSU inadequately controlled by H1-antihistamines in adults; the draft states that it is not possible to determine the most likely cost-effectiveness estimates, and the list price in the company submission is confidential.
  • A Canadian prevalence-based model (conference poster) estimated that remibrutinib coverage would reduce the productivity burden of symptomatic CSU by 69% overall.
  • An omalizumab biosimilar budget impact model across 23 European countries reported omalizumab expenditures exceeding €787 million in 2024 (all indications) and projected €40 million in first-year savings at a 30% discounted biosimilar price.
  • No cost-effectiveness analysis of dupilumab in CSU was found.

Conclusions

Summary: efficacy and safety evidence for barzolvolimab
  • Phase 3 efficacy: EMBARQ-CSU1 (963 participants randomized) and EMBARQ-CSU2 (976 participants randomized) compared barzolvolimab 150 mg every 4 weeks (after a 300 mg loading dose) and 300 mg every 8 weeks (after a 450 mg loading dose) with placebo. Both trials met the primary endpoint of mean change from baseline in UAS7 at Week 12, and the company states that all key secondary endpoints were met. The LS mean change in UAS7 at Week 12 was -20.2 (150 mg) and -20.5 (300 mg) compared with -10.7 (placebo) in EMBARQ-CSU1, and -20.2 and -19.7 compared with -11.4 in EMBARQ-CSU2 (p<.00001 for each dose). Complete response (UAS7=0) at Week 12 was reported in 42.4% and 42.1% compared with 9.3% in EMBARQ-CSU1, and in 45.7% and 44.0% compared with 12.6% in EMBARQ-CSU2.
  • Omalizumab-refractory participants: UAS7=0 at Week 12 was reported in 55.3% (150 mg, N=52) and 44.3% (300 mg, N=52) compared with 9.3% (placebo, N=55) in EMBARQ-CSU1, and in 41.7% (N=44) and 46.4% (N=42) compared with 15.1% (N=43) in EMBARQ-CSU2.
  • Durability: in the phase 2 trial, the company reports UAS7=0 at Week 52 in 71% of participants treated with 150 mg every 4 weeks and 52% treated with 300 mg every 8 weeks, and at Week 76, seven months after the final dose, in 41% and 35%. Phase 3 treatment continues to 52 weeks.
  • Phase 3 safety through the 24-week placebo-controlled period, pooled across both trials (placebo N=645, 150 mg N=648, 300 mg N=641): at least 1 adverse event in 52.7%, 75.6%, and 76.8%; hair color changes in 4.5%, 45.1%, and 51.5%; skin hypopigmentation in 2.5%, 11.0%, and 10.0%; neutropenia in 0.6%, 9.1%, and 11.7%; dysgeusia in 1.4%, 6.8%, and 9.8%; and serious adverse events in 2.3%, 0.9%, and 2.2%. Infection rates were 23.9%, 24.4%, and 23.6%, and the company states that neutropenia was not associated with increased incidence of infections. Anaphylaxis adjudicated as probable was reported in 0 participants with placebo, 2 with 150 mg, and, in the 300 mg group, “1 (occurred after placebo dose)”.
  • Reversibility: the company reports that in phase 2, neutrophil counts returned to baseline after treatment and hair color changes and skin hypopigmentation were reversible after treatment was discontinued. In a phase 2 pigmentation analysis over 76 weeks, 91% of evaluable participants with hair color changes reported resolution by the end of study participation, and 68% of evaluable participants with skin hypopigmentation reported resolution by data cutoff.
Summary: regulatory timing and evidence gaps
  • Regulatory timing: barzolvolimab is in phase 3 development and has no FDA-approved prescribing information. The phase 3 trials were initiated in July 2024, completed enrollment in February 2026, and reported topline results on September 22, 2026 (data cutoff September 9, 2026). The company anticipates additional 24-week phase 3 results in February 2027 and a BLA submission to the FDA in 2027. The ClinicalTrials.gov records give an estimated study completion of 2027-06 for both phase 3 trials, and the phase 3b long-term extension has an estimated primary completion of 2028-09. No FDA expedited program designation for CSU was found. A U.S. composition of matter patent has an estimated expiry in 2034.
  • Publication status: the phase 3 results are available only as topline results in a company press release and investor presentation, and no peer-reviewed publication of them was found; the company plans to present the data at an upcoming medical meeting. Values are not reported for the key secondary endpoints of ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants. The Week 24 UAS7=0 results are presented by the company, and the current ClinicalTrials.gov records list no Week 24 UAS7 outcome.
  • Safety reporting: phase 3 adverse events are reported pooled across both trials through Week 24, with no trial-level counts and no counts of discontinuation for adverse events.
  • Health-related quality of life: baseline DLQI is reported for both phase 3 trials, and no DLQI or other health-related quality of life result after baseline is reported.
  • Immunogenicity: antidrug antibody data come from the phase 1b study with intravenous dosing, in which 57% (20/35) of participants were ADA positive in the publication, without apparent impact on exposure; a poster at the November 2022 data cutoff reported treatment-emergent ADA in 51%. No antidrug antibody results from the phase 2 or phase 3 CSU trials were found.
  • Pharmacokinetics and dosing: no subcutaneous bioavailability, time to peak concentration, or half-life values were found, and no dose regimen proposed for licensure was found. The phase 3 trials test both regimens; retreatment in the phase 3b extension uses a 300 mg loading dose followed by 150 mg every 4 weeks.
  • Price: no published price and no budget impact model for barzolvolimab were found.
  • Population: the phase 3 trials enrolled adults and excluded participants with a history of anaphylaxis; no evidence in pediatric participants was found.
Summary: barzolvolimab and current therapies
  • Approved advanced therapies: omalizumab is indicated for CSU in adults and adolescents 12 years of age and older at 150 mg or 300 mg by subcutaneous injection every 4 weeks, is initiated in a healthcare setting, and carries a boxed warning for anaphylaxis. Dupilumab is indicated for CSU in patients aged 2 years and older, with an adult dosage of 600 mg followed by 300 mg every 2 weeks. Remibrutinib was approved by the FDA in September 2025 as an oral treatment for adults, at 25 mg twice daily. Barzolvolimab is studied at 150 mg every 4 weeks or 300 mg every 8 weeks by subcutaneous injection from 1 mL pre-filled syringes, which the manufacturer states allows potential self-administration at home.
  • Guideline position: the 2026 international guideline recommends add-on omalizumab and suggests add-on dupilumab or remibrutinib for CSU unresponsive to high doses of second-generation H1-antihistamines, states that remibrutinib can be considered especially in patients who do not respond to both high-dose antihistamines and omalizumab, acknowledges restrictions on all three because of their high cost, and notes that treatments under development aim, among other approaches, to reduce mast cell numbers. A network meta-analysis conducted to update the AAAAI/ACAAI joint task force chronic urticaria guideline found with high certainty that standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective, and stated that the safety profile of remibrutinib is less certain and that the impact of dupilumab on quality of life is uncertain.
  • Pivotal trial results, each against its own placebo group: UAS7=0 at Week 12 was reported in 36% with omalizumab 300 mg and 9% with placebo in CSU Trial 1, and in 31.1% with remibrutinib and 10.5% with placebo in REMIX-1 and 27.9% and 6.5% in REMIX-2. With dupilumab, UAS7 = 0 at Week 24 was reported in 32.4% compared with 13.2% in CUPID Study A and 30.1% compared with 17.3% in Study C, and CUPID Study B, in participants with inadequate response to or intolerance of anti-IgE treatment, did not meet its primary endpoint. The barzolvolimab phase 3 trials included omalizumab-refractory participants (results above). No head-to-head trial of barzolvolimab with these therapies was found, and the company states that cross-study comparisons are limited by differences in trial design, statistical methods, patient populations, and dosing schedules.
  • Prices: remibrutinib is listed at $4,521 per 30-day supply (as of January 7, 2026), dupilumab at $4,193.03 per 4-week supply (as of January 1, 2026), and omalizumab at a Genentech-stated list price of approximately $30,000 - $60,000 annually. Omalizumab biosimilar competition became available in 2026, and a negotiated Medicare Maximum Fair Price for Xolair is scheduled to take effect January 1, 2028.
  • Manufacturer positioning: the company describes barzolvolimab as positioned “as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.”